This study confirms the benefit of midostaurin in patients with AML and mutations of FLT3 eligible for intensive chemotherapy, a subgroup that includes 30% of adults with this disease and is associated with adverse outcomes [30–32]. The gene discussed is FLT3; the disease is acute myeloid leukemia.